UGT1A1 gene polymorphism: Impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer

Por Schulz, Christoph, Heinemann, Volker, Schalhorn, Andreas, Moosmann, Nikolas, Zwingers, Thomas, Boeck, Stefan, Giessen, Clemens, Stemmler, Hans-Joachim
Publicado em 2009

Mortality Risk for Acute Cholangitis (MAC): a risk prediction model for in-hospital mortality in patients with acute cholangitis

Por Schneider, Jochen, Hapfelmeier, Alexander, Thöres, Sieglinde, Obermeier, Andreas, Schulz, Christoph, Pförringer, Dominik, Nennstiel, Simon, Spinner, Christoph, Schmid, Roland M., Algül, Hana, Huber, Wolfgang, Weber, Andreas
Publicado no BMC Gastroenterol (2016)

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic co...

Por Teschendorf Christian, Sieber Markus, Denzlinger Claudio, Bangerter Markus, Mayerle Julia, Vehling-Kaiser Ursula, Kullmann Frank, Stintzing Sebastian, Hinke Axel, von Weikersthal Ludwig, Giessen Clemens, Freiberg-Richter Jens, Schulz Christoph, Modest Dominik, Moosmann Nicolas, Aubele Philipp, Heinemann Volker
Publicado em 2011-08-01

A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic co...

Por Giessen, Clemens, von Weikersthal, Ludwig Fischer, Hinke, Axel, Stintzing, Sebastian, Kullmann, Frank, Vehling-Kaiser, Ursula, Mayerle, Julia, Bangerter, Markus, Denzlinger, Claudio, Sieber, Markus, Teschendorf, Christian, Freiberg-Richter, Jens, Schulz, Christoph, Modest, Dominik Paul, Moosmann, Nicolas, Aubele, Philipp, Heinemann, Volker
Publicado em 2011